Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Last updated: March 20, 2024
Sponsor: Vanda Pharmaceuticals
Overall Status: Active - Recruiting

Phase

3

Condition

Vomiting

Treatment

Tradipitant

Clinical Study ID

NCT06138613
VP-VLY-686-3403
  • Ages 18-75
  • All Genders

Study Summary

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • History of Motion Sickness
  • Age 18-75

Exclusion

Exclusion Criteria:

  • Nausea-inducing disorder other than motion sickness
  • BMI > 40
  • History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Tradipitant
Phase: 3
Study Start date:
February 27, 2023
Estimated Completion Date:
April 30, 2025

Study Description

This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.

Connect with a study center

  • Santa Monica Clinical Trials

    Santa Monica, California 90404
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.